JAN 20, 2022 7:30 AM PST

Researchers Stumble Upon Cancer Drug While Studying Flesh-Eating Bacteria

WRITTEN BY: Tara Fernandes

Scientists studying a neglected tropical disease have made a chance discovery—a promising therapeutic target for a deadly blood cancer. Institut Pasteur and Inserm researchers were investigating Buruli ulcers: infectious open sores caused by Mycobacterium ulcerans, a pathogen from the family of bacteria that cause leprosy and tuberculosis.

Buruli ulcers are a form of skin necrosis triggered by a toxin called mycolactone that the bacteria secrete. In previous studies, the scientists found that mycolactone affects the endoplasmic reticulum, a cell organelle that plays various roles, including producing hormones and lipids. The toxin blocks the function of the endoplasmic reticulum, ultimately resulting in the buildup of proteins inside the cell, causing it to self-destruct.

Interestingly, in their latest work, the researchers show that mycolactone is also incredibly lethal towards multiple myeloma cells, a cancer of mature plasma cells in the bone marrow. The researchers demonstrate that the toxin can kill tumor cells in animal models and tumor samples from patient biopsies. Most promisingly, mycolactone is harmless to healthy cells and is highly toxic to multiple myeloma cells that have become resistant to existing cancer therapies.

Factors such as radiation exposure and family history can contribute to an elevated risk of multiple myeloma, although the exact causes of the cancer are still unknown. The cancer is treated with steroids, stem cell transplants, or a class of chemotherapies known as proteasome inhibitors. While these therapies work well initially—particularly in patients at the early stages of the disease—over time, patients tend to become resistant to the treatment, and the cancer relapses.

The discovery of mycolactone’s powerful, selective effects on multiple myeloma cells paves the way for next-generation therapies with the potential to keep tumors in remission for longer, or possibly even permanently.

 

About the Author
PhD
Interested in health technology and innovation.
You May Also Like
JAN 26, 2022
Cell & Molecular Biology
An Antibacterial Molecule Links Chronic Inflammatory Disease & Gut Microbiome
JAN 26, 2022
An Antibacterial Molecule Links Chronic Inflammatory Disease & Gut Microbiome
The gut microbiome is crucial to human health, but the human body has to keep the microorganisms within it in check. We ...
FEB 26, 2022
Health & Medicine
Vitamin D Deficiency Linked to Increased Risk of COVID Infection and More Severe Symptoms
FEB 26, 2022
Vitamin D Deficiency Linked to Increased Risk of COVID Infection and More Severe Symptoms
A century ago before effective antibiotics were available, tuberculosis patients were placed outside on sunny days becau ...
FEB 28, 2022
Plants & Animals
Fecal Microbiota Transplant Promising for Peanut Allergy Patients
FEB 28, 2022
Fecal Microbiota Transplant Promising for Peanut Allergy Patients
Peanut allergies can be fatal, leading to severe allergic reactions that can restrict breathing and digestive problems, ...
MAR 15, 2022
Drug Discovery & Development
Moderna begins clinical trial for its second HIV vaccine
MAR 15, 2022
Moderna begins clinical trial for its second HIV vaccine
On Monday, March 14, the biotech company Moderna announced that the first participant had been dosed with a ne ...
MAR 22, 2022
Microbiology
When Different Microbes are Present, Antibiotics are Less Effective
MAR 22, 2022
When Different Microbes are Present, Antibiotics are Less Effective
Although antibiotic resistance is becoming a problem, many bacterial infections can still be prevented or eliminated wit ...
APR 25, 2022
Microbiology
How a Serious Infection Can Cause Mood Disorders
APR 25, 2022
How a Serious Infection Can Cause Mood Disorders
When a pathogen invades the body, the immune system has to mount a response, which involves inflammation. But inflammati ...
Loading Comments...